Morgan Stanley lowered the firm’s price target on Cryoport (CYRX) to $7 from $8 and keeps an Equal Weight rating on the shares. Following the divestiture of CRYOPDP, the firm is updating its model and notes that its FY25 revenue estimate moves to $169M from $245M and that its FY26 revenue view moves to $188M from $268M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX:
- CryoPort’s Financial Outlook: Hold Rating Amid Revenue Adjustments and Discounted Valuation
- CYRX Upcoming Earnings Report: What to Expect?
- Strategic Realignment and Revenue Projections Underpin Buy Rating for CryoPort
- UBS Says It’s Time to Go Bargain Hunting; Here Are 2 Stocks Poised for a Rebound
- CryoPort’s Strategic Divestiture to DHL: Balancing Debt Reduction and Revenue Challenges